Pharmaceuticals

Entyvio Market 2026 strengthening with gastrointestinal disease treatment demand

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Entyvio Market Expected To Change Between 2026 And 2030?

The historical expansion was driven by the shortcomings of traditional immunosuppressive treatments, an increasing prevalence of inflammatory bowel disease, the robust clinical effectiveness demonstrated by vedolizumab, the widespread acceptance of biologics among gastroenterologists, and the granting of regulatory clearances for uc and cd.

The projected growth during the forecast period is attributable to several factors, including the increasing global prevalence of IBD, the expansion of treatments into earlier stages of the disease, enhanced diagnostic rates, improved access to biologic therapies, and a stronger focus on long-term disease management.

Key trends observed in the forecast period encompass the rising utilization of gut-selective biologic therapies, increasing adoption in moderate to severe IBD cases, a growing preference for targeted integrin inhibition, the broader implementation of long-term maintenance therapy, and a heightened emphasis on safety when compared to systemic immunosuppressants.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19901&type=smp

Which Economic Or Industry Drivers Are Impacting The Entyvio Market?

The rising occurrence of inflammatory bowel disease is projected to fuel the expansion of the entyvio market in the future. Inflammatory bowel disease (IBD) encompasses chronic, recurring inflammatory conditions affecting the gastrointestinal (GI) tract, marked by immune system dysfunction that causes persistent inflammation and tissue damage. The growth in IBD cases stems from a mix of genetic susceptibility, environmental aspects like diet and urbanization, lifestyle shifts including elevated stress, and changes in gut microbiota influenced by elements such as antibiotic use and less contact with natural microbes. Entyvio addresses inflammatory bowel disease (IBD) by specifically targeting and inhibiting the alpha4beta7 integrin, thereby reducing the movement of inflammatory cells into the gut. As an illustration, in June 2024, the Centre for Disease Control and Prevention, a US-based non-profit organization, estimated that the prevalence of inflammatory bowel disease (IBD) in the United States is between 2.4 to 3.1 million people. Consequently, the growing prevalence of inflammatory bowel disease is propelling the growth of the entyvio market.

How Is The Entyvio Market Structured Across Different Segments?

The entyvio market covered in this report is segmented –

1) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

2) By Treatment Line: First-Line Therapy, Second-Line Therapy

3) By Indication: Ulcerative Colitis (UC), Crohn’s Disease (CD)

4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Trends Are Shaping The Future Of The Entyvio Market?

Leading companies within the entyvio market are concentrating on developing maintenance treatments to enhance the enduring management of inflammatory bowel disease (IBD). These maintenance therapies involve continuous medical interventions designed to control chronic ailments, prevent disease progression, and sustain a stable or improved health status after achieving initial treatment goals. The objective of these treatments is to lower the likelihood of recurrence, adverse events, or symptoms over an extended period, thereby securing prolonged disease management and a higher quality of life for individuals. As an illustration, in April 2024, Takeda pharmaceutical, a US based pharmaceutical company, obtained authorization from the Food and Drug Administration, a US-based federal agency, for the subcutaneous (SC) method of administration for ongoing treatment in adults suffering from moderately to severely active Crohn’s disease (CD), following initial induction therapy using intravenous (IV) Entyvio. This subcutaneous alternative facilitates self-application via a pre-filled pen, offering greater ease for patients to continue their therapy at home subsequent to an initial IV infusion received during the induction period. Research from clinical trials has demonstrated that Entyvio considerably alleviates symptoms and brings about remission in individuals with Crohn’s disease when contrasted with a placebo.

Which Major Players Dominate The Entyvio Market?

Major companies operating in the entyvio market are Takeda Pharmaceutical Company Limited

Read the full entyvio market report here:

https://www.thebusinessresearchcompany.com/report/entyvio-global-market-report

What Are The Top-Performing Regions Within The Entyvio Market?

North America was the largest region in the Entyvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Entyvio Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19901&type=smp

Browse Through More Reports Similar to the Global Entyvio Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795